Category Archives: Myocardial Infarction

BACKGROUND: Patients lifestyle changes aftermyocardial infarctionreduce the risk ofinfarction. Nursing interventions are important for the initiation and maintenance of lifestyle adaptation. The aim of this study was to evaluate the effect of education and telephone follow-up intervention based on the Roy Adaptation Model for improvingmyocardial infarctionpatients self-efficacy, quality of life and lifestyle adaptation Continue reading →

Evidence Rating Level: 1 (Excellent) Percutaneous coronary intervention (PCI) is a highly effective treatment in coronary artery disease. However, the optimal strategy of antiplatelet therapy after PCI remains debated. The randomized, controlled GLOBAL LEADERS study found that post-PCI, ticagrelor monotherapy (a P2Y12 inhibitor) following one month of dual antiplatelet therapy (DAPT) with aspirin was safe, but not superior to conventional DAPT in reducing the composite of all-cause mortality or new Q-wave myocardial infarction (MI). Continue reading →

Injections of stem cellseither a patients own or from a donorinto the hearts of people with cardiac conditions has been shown in some cases to improve heart function. How the cells help has been a mystery. A paper in Nature today (November 27) shows that activation of an innate immune response can explain, and even recapitulate, the beneficial effects of stem cell transplants in the hearts of mice Continue reading →

The Global Myocardial Infarction Therapeutics Market report explores the essential factors such as industry situations, market demands, market players adopted business strategies and their growth scenario. Continue reading →

Updated Results of TCAR Surveillance Project Presented at 2019 VEITHsymposium NEW YORK, New York November 22, 2019 Silk Road Medical, Inc. announced the presentation of real-world data for the treatment of patients with carotid artery disease at risk for stroke at theVEITHsymposium. In a headline presentation, Dr Continue reading →

Alex Nowbar reviews the latest research from the top medical journals. Annals of Internal Medicine Bedside test for raised intracranial pressure Just lie back and close your eyes Continue reading →

The prospect of an "off-the-shelf" product, rather than one that needs to be grown individually for each patient, is a "very exciting" proposition, say experts discussing new data that will be presented at the forthcoming American Society of Hematology (ASH) meeting. For the last few years, much attention has been focused on chimeric antigen receptor (CAR) T cell products for the treatment of leukemias and lymphomas. These products have been taking center stage at the meeting, mainly "because of their incredible efficacy," commented ASH Secretary Robert A. Continue reading →

The aim of the study was to determine the roles of microRNA (miR)-146a onmyocardial infarction(MI)-induced heart failure and cardiac remodeling. Experiments were carried out in Sprague-Dawley rats treated with ligation of left coronary artery to induce heart failure, and in primary neonatal rat cardiac fibroblasts (CFs) and cardiomyocytes treated with angiotensin (Ang) II. Four weeks after MI, rats were injected with miR-146a antagomiR or agomiR via tail vein. Continue reading →

AIM: The aim of the study was to determine the frequency of bacterial or fungal mouth infections inmyocardial infarctionpatients treated with primary coronary intervention. A total of 128 patients took part in the study (68 patients in the study group and 60 in the control group). The medical histories of the patients were taken, and the following tests were performed: a physical examination and an oral hygiene assessment. Continue reading →

PHILADELPHIA The investigational drug apabetalone (Resverlogix) did not reduce the risk for major adverse cardiovascular events (MACE) in BETonMACE, a phase3 trial of patients who had recent acute coronary syndrome (ACS), type2 diabetes, and low HDL cholesterol. But this might be because the trial of this novel agent which acts at the epigenetic level, turning genes on and off was underpowered, both the lead author and an outside expert suggest. Apabetalone inhibits bromodomain and extra-terminal (BET) proteins, which are epigenetic transcription modulators of inflammation, thrombogenesis, and lipoprotein lipid metabolism. Continue reading →